CN113520944A - 一种用于快速消痘的凝胶组合物及其制备方法与用途 - Google Patents
一种用于快速消痘的凝胶组合物及其制备方法与用途 Download PDFInfo
- Publication number
- CN113520944A CN113520944A CN202110857916.9A CN202110857916A CN113520944A CN 113520944 A CN113520944 A CN 113520944A CN 202110857916 A CN202110857916 A CN 202110857916A CN 113520944 A CN113520944 A CN 113520944A
- Authority
- CN
- China
- Prior art keywords
- extract
- phase
- parts
- root extract
- gel composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 41
- 206010000496 acne Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 88
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 28
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 24
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 17
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 17
- 241000186660 Lactobacillus Species 0.000 claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 16
- 230000004151 fermentation Effects 0.000 claims abstract description 16
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 12
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 12
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 12
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004359 castor oil Substances 0.000 claims abstract description 12
- 235000019438 castor oil Nutrition 0.000 claims abstract description 12
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 12
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000207934 Eriodictyon Species 0.000 claims abstract description 11
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 11
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 11
- 239000001113 gentiana lutea root extract Substances 0.000 claims abstract description 10
- 229940082942 gentiana lutea root extract Drugs 0.000 claims abstract description 10
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 claims abstract description 10
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 9
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 7
- 239000001642 eugenia caryophyllata l. bud extract Substances 0.000 claims abstract description 6
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims abstract description 6
- 229940051810 licorice root extract Drugs 0.000 claims abstract description 6
- 235000020725 licorice root extract Nutrition 0.000 claims abstract description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 4
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 claims abstract description 4
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims abstract description 4
- 239000000499 gel Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 27
- 239000002994 raw material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 241000972673 Phellodendron amurense Species 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 229940082463 angelica sinensis root extract Drugs 0.000 claims description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 229920006037 cross link polymer Polymers 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 6
- 235000011797 eriodictyol Nutrition 0.000 claims description 6
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims description 6
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims description 6
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 6
- 239000008274 jelly Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 5
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 5
- 229940104261 taurate Drugs 0.000 claims description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 5
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 4
- 241000628997 Flos Species 0.000 claims description 3
- 244000297179 Syringa vulgaris Species 0.000 claims description 3
- 235000004338 Syringa vulgaris Nutrition 0.000 claims description 3
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 4
- 240000000724 Berberis vulgaris Species 0.000 abstract 1
- 235000016068 Berberis vulgaris Nutrition 0.000 abstract 1
- 239000001180 angelica archangelica l. root extract Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 38
- 239000000047 product Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000002374 sebum Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 230000007794 irritation Effects 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 101800005049 Beta-endorphin Proteins 0.000 description 2
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 2
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 2
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000003409 Gentiana lutea Species 0.000 description 2
- 235000002873 Gentiana lutea Nutrition 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 206010040830 Skin discomfort Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 108010025083 TRPV1 receptor Proteins 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 241001288870 Angelica polymorpha Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 244000017029 Eriodictyon californicum Species 0.000 description 1
- 235000002683 Eriodictyon californicum Nutrition 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930002966 sinomenine Natural products 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229930189533 tanshinol Natural products 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于快速消痘的凝胶组合物及其制备方法与用途，该组合物包含：丁二醇、海藻糖、乳酸杆菌/北美圣草发酵产物提取物、辛基十二醇、广藿香叶提取物、丙烯酰二甲基牛磺酸铵/VP共聚物、黄龙胆根提取物、对羟基苯乙酮、水、1,2‑己二醇、聚丙烯酸酯交联聚合物‑6、叔丁醇、黄檗树皮提取物、积雪草提取物、丹参根提取物、丁香花蕾提取物、黄芩根提取物、当归根提取物、甘草根提取物、PPG‑26‑丁醇聚醚‑26、PEG‑40氢化蓖麻油、羟乙基纤维素、EDTA二钠、CI19140。本发明还提供了该组合物的制备方法与用途。本发明的组合物能针对性解决不同原因引起的皮肤痤疮症状，并能促进皮肤抗炎、抗敏及修复功能。
Description
技术领域
本发明涉及一种用于化妆品领域的解决皮肤痤疮症状的组合物及其制备方法与用途，具体地，涉及一种用于快速消痘的凝胶组合物及其制备方法与用途。
背景技术
痘痘又名痤疮，是一种毛囊皮肤腺的慢性炎症疾病，一般好发于面部及躯干，具有粉刺、丘疹、脓疱、结节和囊肿等临床症状，常伴有皮脂溢出。引起痤疮的因素很多，其中主要包括雄性激素水平异常、皮脂分泌量过多、毛囊周围细胞角化异常和炎症反应这四类。
雄性激素水平直接影响着皮脂腺的发育，当体内雄性激素水平提升，皮脂分泌旺盛，此外若雄激素受体异常也会导致皮脂分泌增加。皮脂分泌量过多是痤疮发生主要原因。同时毛囊周围细胞角化异常导致毛囊口变小、狭窄、堵塞，从而导致皮脂无法正常排出而堵塞，形成粉刺。因为皮脂的溢出而导致丙酸杆菌繁殖增加，痤疮丙酸杆菌通过促使角质形成细胞、皮脂腺细胞和单核细胞的Toll样受体表达而导致不同程度的炎症。同时痤疮丙酸杆菌水解皮脂中的甘油三酯脂产生游离的脂肪酸，游离的脂肪酸刺激毛囊及毛囊周围发生炎症反应，进一步加重痤疮症状。由于痤疮产生机理及原因的复杂性，目前仍无特效药物和有效的方法治疗皮肤痤疮。
发明内容
本发明的目的是提供一种适用于所有肤质的快速消痘的凝胶组合物制备及在护肤品中的应用，能够解决现有问题，针对不同原因引起的皮肤痤疮症状，并能促进皮肤抗炎、抗敏以及修复功能等。
为了达到上述目的，本发明提供了一种用于快速消痘的凝胶组合物，其中，该组合物包含A相、B相、C相、D相；A相包含丁二醇、海藻糖、乳酸杆菌/北美圣草发酵产物提取物、辛基十二醇、广藿香叶提取物、丙烯酰二甲基牛磺酸铵/VP共聚物、黄龙胆根提取物、对羟基苯乙酮，以及水；B相包含1,2-己二醇、聚丙烯酸酯交联聚合物-6、叔丁醇、黄檗树皮提取物、积雪草提取物、丹参根提取物、丁香花蕾提取物、黄芩根提取物、当归根提取物；C相包含甘草根提取物、PPG-26-丁醇聚醚-26、PEG-40氢化蓖麻油；D相包含羟乙基纤维素、EDTA二钠、CI19140。
上述的用于快速消痘的凝胶组合物，其中，所述的组合物中按重量份数计包含：丁二醇4～6份、海藻糖1～3份、乳酸杆菌/北美圣草发酵产物提取物4～6份、辛基十二醇1～3份、广藿香叶提取物2～4份、丙烯酰二甲基牛磺酸铵/VP共聚物2～4份、黄龙胆根提取物0.5～1.5份、对羟基苯乙酮0.4～0.6份、1,2-己二醇1～3份、聚丙烯酸酯交联聚合物-6 2～4份、叔丁醇2～4份、黄檗树皮提取物0.5～1.5份、积雪草提取物0.5～1.5份、丹参根提取物0.4～0.6份、丁香花蕾提取物0.4～0.6份、黄芩根提取物0.5～1.5份、当归根提取物0.4～0.6份、甘草根提取物0.5～1.5份、PPG-26-丁醇聚醚-26 0.5～1.5份、PEG-40氢化蓖麻油1～3份、羟乙基纤维素0.5～1.5份、EDTA二钠0.4～0.6份、CI191400.4～0.6份。
上述的用于快速消痘的凝胶组合物，其中，所述的组合物中按质量百分比计包含：丁二醇5％、海藻糖2％、乳酸杆菌/北美圣草发酵产物提取物5％、辛基十二醇2％、广藿香叶提取物3％、丙烯酰二甲基牛磺酸铵/VP共聚物3％、黄龙胆根提取物1％、对羟基苯乙酮0.5％、1,2-己二醇2％、聚丙烯酸酯交联聚合物-6 3％、叔丁醇3％、黄檗树皮提取物1％、积雪草提取物1％、丹参根提取物0.5％、丁香花蕾提取物0.5％、黄芩根提取物1％、当归根提取物0.5％、甘草根提取物1％、PPG-26-丁醇聚醚-26 1％、PEG-40氢化蓖麻油2％、羟乙基纤维素1％、EDTA二钠0.5％、CI19140 0.5％。
上述的用于快速消痘的凝胶组合物，其中，所述的组合物中按质量百分比计加水到100％。
本发明还提供了一种上述的用于快速消痘的凝胶组合物的制备方法，其中，所述的方法包含：步骤1、按比例称量各原料，并分为A相、B相、C相、D相；步骤2、将A相边加热边搅拌；步骤3、向A相中加入B相，快速搅拌至均匀透明啫喱状；步骤4、加降温边搅拌，再加入C相、D相，搅拌至均匀。
上述的用于快速消痘的凝胶组合物的制备方法，其中，所述的步骤3中，当A相温度达到60℃时，加入B相。
上述的用于快速消痘的凝胶组合物的制备方法，其中，所述的步骤4中，加降温边搅拌，待冷却至40℃时，再加入C相、D相。
本发明也提供了一种上述的方法制备的用于快速消痘的凝胶组合物的用途，其中，所述的组合物用于制备护肤品；所述的护肤品包含净痘膏。
本发明提供的用于快速消痘的凝胶组合物及其制备方法与用途具有以下优点：
本发明专利涉及的快速消除痤疮的凝胶组合物首次将多种植物中药提取物(北美圣草、广藿香、黄龙胆、黄檗、丹参、黄芩、当归、甘草、积雪草等)及微生物发酵物进行组合，适用于各种皮肤痤疮，在快速消除痘痘，淡化痘印的同时，还可以在皮肤表面形成天然屏障，调节皮肤水油平衡。
该组合物在达到快速消痘同时，还具有修复皮肤屏障，保湿锁水，抗炎抑菌等功能，从而改善过敏性肌肤或干燥肌，从而保持皮肤的水润与健康。
具体实施方式
以下对本发明的具体实施方式作进一步地说明。
本发明提供的用于快速消痘的凝胶组合物，包含A相、B相、C相、D相；A相包含丁二醇、海藻糖、乳酸杆菌/北美圣草发酵产物提取物、辛基十二醇、广藿香叶提取物、丙烯酰二甲基牛磺酸铵/VP共聚物、黄龙胆根提取物、对羟基苯乙酮，以及水；B相包含1,2-己二醇、聚丙烯酸酯交联聚合物-6、叔丁醇、黄檗树皮提取物、积雪草提取物、丹参根提取物、丁香花蕾提取物、黄芩根提取物、当归根提取物；C相包含甘草根提取物、PPG-26-丁醇聚醚-26、PEG-40氢化蓖麻油；D相包含羟乙基纤维素、EDTA二钠、CI19140。
优选地，该组合物中按重量份数计包含：丁二醇4～6份、海藻糖1～3份、乳酸杆菌/北美圣草发酵产物提取物4～6份、辛基十二醇1～3份、广藿香叶提取物2～4份、丙烯酰二甲基牛磺酸铵/VP共聚物2～4份、黄龙胆根提取物0.5～1.5份、对羟基苯乙酮0.4～0.6份、1,2-己二醇1～3份、聚丙烯酸酯交联聚合物-6 2～4份、叔丁醇2～4份、黄檗树皮提取物0.5～1.5份、积雪草提取物0.5～1.5份、丹参根提取物0.4～0.6份、丁香花蕾提取物0.4～0.6份、黄芩根提取物0.5～1.5份、当归根提取物0.4～0.6份、甘草根提取物0.5～1.5份、PPG-26-丁醇聚醚-26 0.5～1.5份、PEG-40氢化蓖麻油1～3份、羟乙基纤维素0.5～1.5份、EDTA二钠0.4～0.6份、CI19140 0.4～0.6份。
更优选地，该组合物中按质量百分比计包含：丁二醇5％、海藻糖2％、乳酸杆菌/北美圣草发酵产物提取物5％、辛基十二醇2％、广藿香叶提取物3％、丙烯酰二甲基牛磺酸铵/VP共聚物3％、黄龙胆根提取物1％、对羟基苯乙酮0.5％、1,2-己二醇2％、聚丙烯酸酯交联聚合物-6 3％、叔丁醇3％、黄檗树皮提取物1％、积雪草提取物1％、丹参根提取物0.5％、丁香花蕾提取物0.5％、黄芩根提取物1％、当归根提取物0.5％、甘草根提取物1％、PPG-26-丁醇聚醚-26 1％、PEG-40氢化蓖麻油2％、羟乙基纤维素1％、EDTA二钠0.5％、CI191400.5％。
该组合物中按质量百分比计加水到100％。
本发明中的组合物主要功能成分有：乳酸杆菌/北美圣草(ERIODICTYONCALIFORNICUM)发酵产物提取物、广藿香(POGOSTEMON CABLIN)叶提取物、黄龙胆(GENTIANALUTEA)根提取物、对羟基苯乙酮、黄檗(PHELLODENDRON AMURENSE)树皮提取物、丹参(SALVIA MILTIORRHIZA)根提取物、黄芩(SCUTELLARIA BAICALENSIS)根提取物、当归(ANGELICA POLYMORPHA SINENSIS)根提取物、甘草(GLYCYRRHIZA URALENSIS)根提取物、积雪草(CENTELLA ASIATICA)提取物。
乳酸杆菌/北美圣草(ERIODICTYON CALIFORNICUM)发酵产物提取物是由北美圣草和乳酸菌发酵而成，含有丰富的天然多糖和醣蛋白，形成类皮肤醣蛋白结构，具有高亲肤性，滋润皮肤，补充养分，改善多醣体和醣蛋白涩感，起到镇静舒缓的作用。同时其具有较好的保湿性和抗敏性，减少皮肤刺激。
广藿香(POGOSTEMON CABLIN)叶提取物，是大麻素受体2(CB2)激活剂，激活CB2受体、抑制TRPV1受体，促进β-内啡肽的合成，具有快速舒缓、抗刺激、修复皮肤的作用，能修复敏感肌肤，对外界刺激引起的皮肤不适有很好的缓解效果。
黄檗(PHELLODENDRON AMURENSE)树皮提取物中含有小檗碱对病原微生物具有广谱抑制作用；其含有巴马亭药根碱、黄柏碱、蝙蝠葛任碱、白桥楼碱、黄柏桐等物质，能促进胶原蛋白的生成，结合其抗氧化性，有抗衰的作用
黄龙胆根提取物活化荧光素酶，从而调节特异性皮炎和过敏；活化芳香化酶，调节皮肤雄性激素，控制皮质分泌，缓解皮脂腺堵塞；促进表皮细胞胆甾醇的分泌，改善皮肤的水油平衡。
对羟基苯乙酮对细菌、酵母菌和霉菌具有广谱均衡的抑制作用，不容易水解，对温度和pH值稳定，维持皮肤微生态。
丹参(SALVIA MILTIORRHIZA)根提取物中脂溶性丹参酮具有抗炎和抗菌能力，水溶性成分丹参素、原儿茶醛具有抗氧化和抗菌抗炎作用。丹参根提取物具有抑制皮脂腺细胞增生和缩小皮脂腺细胞体积作用，降低油脂分泌，主要用于皮肤的抗过敏、抗粉刺。
黄岑根提取物中的黄岑苷和黄岑素可以影响花生四烯酸通道，抑制细胞因子的特异性引起的炎症反应；具有极强地广谱性抑菌作用。所以其可以极速消痘同时，还可以增强皮肤抗敏能力。
当归根提取物可以控制血管皮细胞的增殖，具有改善皮肤微循环的作用；其良好的SOD样活性，可以抑制过氧化反应和自由基反应，与磷脂结合，保护生物膜，且可以促进干细胞的增殖，具有极强的修复和抗衰能力。
甘草根提取物可以促进肌细胞和血管内皮细胞的增殖，促进胶原带白的生成，抑制NO的生成，增强皮肤免疫力，抗发炎及降低氧化速度，能防御肌肤敏感现象，安抚舒缓过敏或受刺激的皮肤。
积雪草提取物为植物胶原蛋白，具有消肿解毒祛脓疮的作用；同时其可以促进皮肤胶原蛋白再生，增强细胞基底层细胞活力，调节皮肤免疫力。
本发明还提供了该用于快速消痘的凝胶组合物的制备方法，包含：步骤1、按比例称量各原料，并分为A相、B相、C相、D相；步骤2、将A相边加热边搅拌；步骤3、向A相中加入B相，快速搅拌至均匀透明啫喱状；步骤4、加降温边搅拌，再加入C相、D相，搅拌至均匀。
步骤3中，当A相温度达到60℃时，加入B相。
步骤4中，加降温边搅拌，待冷却至40℃时，再加入C相、D相。
本发明也提供了该方法制备的用于快速消痘的凝胶组合物的用途，该组合物用于制备护肤品；该护肤品包含净痘膏。
下面结合实施例对本发明提供的用于快速消痘的凝胶组合物及其制备方法与用途做更进一步描述。
实施例1
一种用于快速消痘的凝胶组合物，成分如下表1所示。各原料分别符合相应的国家标准。
表1.组合物配料表(按质量百分比计)。
本实施例还提供了该用于快速消痘的凝胶组合物的制备方法，包含：
步骤1、按比例称量各原料，并分为A相、B相、C相、D相。
步骤2、将A相边加热边搅拌。
步骤3、当A相温度达到60℃时，加入B相，快速搅拌至均匀透明啫喱状。
步骤4、加降温边搅拌，待冷却至40℃时，再加入C相、D相，搅拌至均匀。
本实施例也提供了该方法制备的用于快速消痘的凝胶组合物的用途，该组合物用于制备护肤品；该护肤品包含净痘膏。
实施例2
一种用于快速消痘的凝胶组合物，按重量份数计包含：
丁二醇4份、海藻糖1份、乳酸杆菌/北美圣草发酵产物提取物4份、辛基十二醇1份、广藿香叶提取物2份、丙烯酰二甲基牛磺酸铵/VP共聚物2份、黄龙胆根提取物0.5份、对羟基苯乙酮0.4份、1,2-己二醇1份、聚丙烯酸酯交联聚合物-6 2份、叔丁醇2份、黄檗树皮提取物0.5份、积雪草提取物0.5份、丹参根提取物0.4份、丁香花蕾提取物0.4份、黄芩根提取物0.5份、当归根提取物0.4份、甘草根提取物0.5份、PPG-26-丁醇聚醚-26 0.5份、PEG-40氢化蓖麻油1份、羟乙基纤维素0.5份、EDTA二钠0.4份、CI191400.4份。
然后将该组合物按质量百分比计加水到100％。
本实施例还提供了该用于快速消痘的凝胶组合物的制备方法，包含：
步骤1、按比例称量各原料，并分为A相、B相、C相、D相。
步骤2、将A相边加热边搅拌。
步骤3、当A相温度达到60℃时，加入B相，快速搅拌至均匀透明啫喱状。
步骤4、加降温边搅拌，待冷却至40℃时，再加入C相、D相，搅拌至均匀。
本实施例也提供了该方法制备的用于快速消痘的凝胶组合物的用途，该组合物用于制备护肤品；该护肤品包含净痘膏。
实施例3
一种用于快速消痘的凝胶组合物，按重量份数计包含：
丁二醇6份、海藻糖3份、乳酸杆菌/北美圣草发酵产物提取物6份、辛基十二醇3份、广藿香叶提取物4份、丙烯酰二甲基牛磺酸铵/VP共聚物4份、黄龙胆根提取物1.5份、对羟基苯乙酮0.6份、1,2-己二醇3份、聚丙烯酸酯交联聚合物-6 4份、叔丁醇4份、黄檗树皮提取物1.5份、积雪草提取物1.5份、丹参根提取物0.6份、丁香花蕾提取物0.6份、黄芩根提取物1.5份、当归根提取物0.6份、甘草根提取物1.5份、PPG-26-丁醇聚醚-26 1.5份、PEG-40氢化蓖麻油3份、羟乙基纤维素1.5份、EDTA二钠0.6份、CI19140 0.6份。
然后将该组合物按质量百分比计加水到100％。
本实施例还提供了该用于快速消痘的凝胶组合物的制备方法，包含：
步骤1、按比例称量各原料，并分为A相、B相、C相、D相。
步骤2、将A相边加热边搅拌。
步骤3、当A相温度达到60℃时，加入B相，快速搅拌至均匀透明啫喱状。
步骤4、加降温边搅拌，待冷却至40℃时，再加入C相、D相，搅拌至均匀。
本实施例也提供了该方法制备的用于快速消痘的凝胶组合物的用途，该组合物用于制备护肤品；该护肤品包含净痘膏。
采用各实施例制备的组合物进行测试及评估，具体方式如下。
1.实验对象
实验组(本发明)：50例，男25例，女25例；年龄13-30岁；
对照组(安慰剂-普通保湿液)：50例，男25例，女25例，年龄12-岁。
两组人员的性别、年龄等资料经统计学处理，差异无统计学意义(P>0.05)，两组有可比性。
2.治疗方式，对实验组痘痘处涂抹本发明，对照组痘痘处涂抹普通保湿液，记录消痘时间并作如下评估，记录不适反应的发生。
3.评估标准：
根据皮肤破损、发红、刺痛、脓疮、痘印、出油和闭口的情况进行评价。
痊愈：症状及体征消退95％以上。
显效：临床表现减轻80％-94％。
好转：临表现减轻50％-79％。
无效：临床表现无改善。
4.结果：两组头面部脂溢性皮炎患者治疗结果如下表2所示。
表2.测试结果表。
对实验组与对照组进行差异性分析(P＜0.05)有显著差异，具有统计学意义。实验组有效率明显高于对照组有效率，说明实验组可以快速消除痘痘症状，同时实验组未产生不适发生，说明该发明具有超强效果。
本发明采用的成分中，乳酸杆菌/北美圣草发酵产物提取物含有丰富的天然多糖和醣蛋白，可以形成类皮肤醣蛋白结构，具有高亲肤性，滋润皮肤，补充养分，改善多醣体和醣蛋白涩感，可以镇静舒缓，具有较好的保湿性和抗敏性，减少皮肤刺激。广藿香(POGOSTEMON CABLIN)叶提取物，可以激活CB2受体、抑制TRPV1受体，促进β-内啡肽的合成，可以快速舒缓、抗刺激、修复皮肤，能修复敏感肌肤，对外界刺激引起的皮肤不适有很好的缓解效果。
本发明提供的用于快速消痘的凝胶组合物及其制备方法与用途，在达到快速消痘同时，还具有修复皮肤屏障，保湿锁水，抗炎抑菌等功能，从而改善过敏性肌肤或干燥肌，从而保持皮肤的水润与健康。
尽管本发明的内容已经通过上述优选实施例作了详细介绍，但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后，对于本发明的多种修改和替代都将是显而易见的。因此，本发明的保护范围应由所附的权利要求来限定。
Claims (8)
1.一种用于快速消痘的凝胶组合物，其特征在于，该组合物包含A相、B相、C相、D相；
A相包含丁二醇、海藻糖、乳酸杆菌/北美圣草发酵产物提取物、辛基十二醇、广藿香叶提取物、丙烯酰二甲基牛磺酸铵/VP共聚物、黄龙胆根提取物、对羟基苯乙酮，以及水；
B相包含1,2-己二醇、聚丙烯酸酯交联聚合物-6、叔丁醇、黄檗树皮提取物、积雪草提取物、丹参根提取物、丁香花蕾提取物、黄芩根提取物、当归根提取物；
C相包含甘草根提取物、PPG-26-丁醇聚醚-26、PEG-40氢化蓖麻油；
D相包含羟乙基纤维素、EDTA二钠、CI19140。
2.如权利要求1所述的用于快速消痘的凝胶组合物，其特征在于，所述的组合物中按重量份数计包含：丁二醇4～6份、海藻糖1～3份、乳酸杆菌/北美圣草发酵产物提取物4～6份、辛基十二醇1～3份、广藿香叶提取物2～4份、丙烯酰二甲基牛磺酸铵/VP共聚物2～4份、黄龙胆根提取物0.5～1.5份、对羟基苯乙酮0.4～0.6份、1,2-己二醇1～3份、聚丙烯酸酯交联聚合物-6 2～4份、叔丁醇2～4份、黄檗树皮提取物0.5～1.5份、积雪草提取物0.5～1.5份、丹参根提取物0.4～0.6份、丁香花蕾提取物0.4～0.6份、黄芩根提取物0.5～1.5份、当归根提取物0.4～0.6份、甘草根提取物0.5～1.5份、PPG-26-丁醇聚醚-26 0.5～1.5份、PEG-40氢化蓖麻油1～3份、羟乙基纤维素0.5～1.5份、EDTA二钠0.4～0.6份、CI19140 0.4～0.6份。
3.如权利要求2所述的用于快速消痘的凝胶组合物，其特征在于，所述的组合物中按质量百分比计包含：丁二醇5％、海藻糖2％、乳酸杆菌/北美圣草发酵产物提取物5％、辛基十二醇2％、广藿香叶提取物3％、丙烯酰二甲基牛磺酸铵/VP共聚物3％、黄龙胆根提取物1％、对羟基苯乙酮0.5％、1,2-己二醇2％、聚丙烯酸酯交联聚合物-6 3％、叔丁醇3％、黄檗树皮提取物1％、积雪草提取物1％、丹参根提取物0.5％、丁香花蕾提取物0.5％、黄芩根提取物1％、当归根提取物0.5％、甘草根提取物1％、PPG-26-丁醇聚醚-26 1％、PEG-40氢化蓖麻油2％、羟乙基纤维素1％、EDTA二钠0.5％、CI19140 0.5％。
4.如权利要求3所述的用于快速消痘的凝胶组合物，其特征在于，所述的组合物中按质量百分比计加水到100％。
5.一种如权利要求1～4中任意一项所述的用于快速消痘的凝胶组合物的制备方法，其特征在于，所述的方法包含：
步骤1、按比例称量各原料，并分为A相、B相、C相、D相；
步骤2、将A相边加热边搅拌；
步骤3、向A相中加入B相，快速搅拌至均匀透明啫喱状；
步骤4、加降温边搅拌，再加入C相、D相，搅拌至均匀。
6.如权利要求5所述的用于快速消痘的凝胶组合物的制备方法，其特征在于，所述的步骤3中，当A相温度达到60℃时，加入B相。
7.如权利要求5所述的用于快速消痘的凝胶组合物的制备方法，其特征在于，所述的步骤4中，加降温边搅拌，待冷却至40℃时，再加入C相、D相。
8.一种如权利要求5所述的方法制备的用于快速消痘的凝胶组合物的用途，其特征在于，所述的组合物用于制备护肤品；所述的护肤品包含净痘膏。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110857916.9A CN113520944A (zh) | 2021-07-28 | 2021-07-28 | 一种用于快速消痘的凝胶组合物及其制备方法与用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110857916.9A CN113520944A (zh) | 2021-07-28 | 2021-07-28 | 一种用于快速消痘的凝胶组合物及其制备方法与用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113520944A true CN113520944A (zh) | 2021-10-22 |
Family
ID=78121237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110857916.9A Pending CN113520944A (zh) | 2021-07-28 | 2021-07-28 | 一种用于快速消痘的凝胶组合物及其制备方法与用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113520944A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652624A (zh) * | 2022-04-27 | 2022-06-24 | 广州市丽泽化妆品有限公司 | 一种修护面霜及其制备方法 |
| CN115634165A (zh) * | 2022-10-09 | 2023-01-24 | 江苏集萃新型药物制剂技术研究所有限公司 | 抗痤疮的纳米制剂、凝胶组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176567A (zh) * | 2016-08-24 | 2016-12-07 | 广东芭薇生物科技股份有限公司 | 一种双层护肤乳液及其制备方法 |
| CN110652486A (zh) * | 2019-11-12 | 2020-01-07 | 江苏逸洁生物科技股份有限公司 | 一种药物祛痘啫喱 |
| CN110755321A (zh) * | 2019-11-15 | 2020-02-07 | 上海百好博化工有限公司 | 一种用于快速舒敏修护的组合物及制备方法与用途 |
-
2021
- 2021-07-28 CN CN202110857916.9A patent/CN113520944A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176567A (zh) * | 2016-08-24 | 2016-12-07 | 广东芭薇生物科技股份有限公司 | 一种双层护肤乳液及其制备方法 |
| CN110652486A (zh) * | 2019-11-12 | 2020-01-07 | 江苏逸洁生物科技股份有限公司 | 一种药物祛痘啫喱 |
| CN110755321A (zh) * | 2019-11-15 | 2020-02-07 | 上海百好博化工有限公司 | 一种用于快速舒敏修护的组合物及制备方法与用途 |
Non-Patent Citations (1)
| Title |
|---|
| 上海梦希生物科技有限公司: "《U净悦舒缓凝胶》", 《国产普通化妆品备案信息》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652624A (zh) * | 2022-04-27 | 2022-06-24 | 广州市丽泽化妆品有限公司 | 一种修护面霜及其制备方法 |
| CN114652624B (zh) * | 2022-04-27 | 2023-09-19 | 广州市丽泽化妆品有限公司 | 一种修护面霜及其制备方法 |
| CN115634165A (zh) * | 2022-10-09 | 2023-01-24 | 江苏集萃新型药物制剂技术研究所有限公司 | 抗痤疮的纳米制剂、凝胶组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111631993B (zh) | 一种含苦参和厚朴提取物的组合物及其应用的化妆品 | |
| CN113520944A (zh) | 一种用于快速消痘的凝胶组合物及其制备方法与用途 | |
| CN113274331B (zh) | 一种祛痘抗炎组合物及其制备方法与应用 | |
| CN109646358B (zh) | 一种具有控油祛痘功效的复方植物提取物及其应用 | |
| CN112426390A (zh) | 一种天然中药祛痘组合物及其制备方法 | |
| CN109288931A (zh) | 一种治疗婴幼儿湿疹的组合物，制剂及制备方法和应用 | |
| CN111956573A (zh) | 一种婴儿水分霜及其制备方法 | |
| CN111743831A (zh) | 一种祛痘组合物 | |
| CN109498523A (zh) | 一种防皲裂护肤品及其制备 | |
| CN116350563B (zh) | 一种植物共发酵组合物及其制备方法和应用 | |
| CN116889539B (zh) | 一种舒缓抗敏组合物及其制备方法、应用 | |
| CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
| CN110974775A (zh) | 一种含葛仙米的舒敏组合物及其制备方法和应用 | |
| CN111529468A (zh) | 一种补水保湿的面膜精华液及其制备方法 | |
| CN108703911B (zh) | 一种具有保湿美白功效的组合物及其制备方法和应用 | |
| CN113491664A (zh) | 一种用于快速缓解瘙痒的组合物及其制备方法与用途 | |
| CN113440470A (zh) | 一种有效缓解熬夜皮肤不适感的组合物其制备方法与用途 | |
| CN109662926A (zh) | 一种聚水保湿精华露及其制备方法 | |
| CN109966193A (zh) | 一种改善皮肤功能的组合物及其制备方法和应用 | |
| CN115025150A (zh) | 一种治疗炎症性皮肤病的中药组合物、洗剂 | |
| CN113476394A (zh) | 一种有效调节皮肤干燥脱屑的组合物及其制备方法与用途 | |
| CN114668701A (zh) | 一种婴儿湿疹用天然富硒植物精华舒缓乳液及其制备方法 | |
| CN107898684B (zh) | 一种含有鲜姜汁的植物提取物组合物及其制备方法和应用 | |
| CN111297749A (zh) | 一种含大麻提取物的护手霜及其制备方法 | |
| CN113440457A (zh) | 一种白及组方及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |